Recent Advances in the Treatment and Management of Moderate-to-Severe Atopic Dermatitis: What's New in Biologic Therapies

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2019 to June 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Sanofi Genzyme and Regeneron Pharmaceuticals

Description:
Atopic dermatitis (AD) is a common, chronic inflammatory skin disease characterized by periods of acute disease flare that may include painful burning sensations and persistent itching. AD occurs more frequently in adulthood, is often accompanied by co-morbidities such as rhinitis and asthma and can severely affect quality of life. AD is the leading cause of non-fatal disease burden of skin conditions, effecting approximately 27.6 million people with moderate to severe eczema or atopic dermatitis in the United States with an estimated annual direct and indirect cost of $5 billion dollars. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Current atopic dermatitis treatments attempt to reduce inflammation and itchiness to maintain the protective integrity of the skin and have shown the ability to manage the disease in the short term but have had troubles with long term efficacy. Thankfully advances in the understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. Fortunately, several new treatments, including novel monoclonal antibodies or targeted therapies, such as Janus Kinase Inhibitors (JAK) and PDE4 inhibitors, have shown improved efficacy and safety, offering patients the potential for improved outcomes and quality of life.

Upon completion of this activity, participants will be able to:

  • Examine the impact of inadequately treated moderate-to-severe atopic dermatitis on physical and mental health, quality of life, costs and work productivity

  • Analyze individualized treatment plans for moderate-to-severe AD based on current guideline recommendations for AD, real world safety and efficacy data, comorbidities, and patient quality of life

  • Explore the role of newer biologic therapies in adolescent patients with moderate-to-severe atopic dermatitis whose disease is inadequately controlled

  • Identify patients who may benefit from biologic therapy in the management of moderate-to-severe atopic dermatitis

  • Discuss benefit design strategies to improve overall patient outcomes in atopic dermatitis

  • Assess the managed care considerations of biologic therapies by exploring where these agents fit in the atopic dermatitis management paradigm
     

Faculty: Adelaide A. Hebert, MD
Professor of Dermatology and Pediatrics
UTHealth McGovern Medical School, Houston

Disclosure:

Dr. Hebert serves on an advisory board for Demira, Galderma, Medimetrics, and Pfizer. She serves as a consultant for Demira, Galderma, Pfizer, and Leo. She has received grant/research support from Demira, Pfizer, and Leo. She serves on the speaker's bureau for Demira, Galderma, and Pfizer. Her presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Sanofi Genzyme and Regeneron Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue